{
  "ticker": "LLY",
  "target_date": "2025-06-16",
  "actual_date": "2025-06-16",
  "collected_at": "2025-12-08T11:53:49.159908",
  "price": {
    "open": 818.68,
    "high": 821.98,
    "low": 802.82,
    "close": 804.62841796875,
    "volume": 2821800,
    "change_1d_pct": -1.44,
    "change_7d_pct": 5.47,
    "change_30d_pct": -1.75
  },
  "technicals": {
    "rsi_14": 84.93,
    "sma_20": 756.65,
    "sma_50": 770.96,
    "macd": 11.229,
    "macd_signal": 1.304,
    "macd_histogram": 9.925,
    "bb_upper": 827.49,
    "bb_lower": 685.82,
    "price_vs_sma20_pct": 6.34,
    "price_vs_sma50_pct": 4.37,
    "volume_ratio": 0.84
  },
  "fundamentals": {
    "market_cap": 891853471744,
    "pe_ratio": 48.744,
    "forward_pe": 43.904015,
    "price_to_book": 37.457268,
    "price_to_sales": 15.009365,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.53,
    "pct_from_52w_low": 59.49
  },
  "macro": {
    "spy": {
      "price": 599.24,
      "change_1d_pct": 0.95,
      "change_7d_pct": 0.59
    },
    "vix": {
      "level": 19.11,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.45
    },
    "dollar_index": {
      "level": 98.0
    },
    "gold": {
      "price": 3396.4
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports",
      "source": "Yahoo",
      "datetime": 1750117742,
      "summary": "The drug maker's acquisition bid includes a payment of almost $1 billion upfront for Verve, and a further $300 million based on the genetic medicines company achieving certain clinical milestones, the report said, citing people familiar with the matter.  Verve Therapeutics is currently developing a ",
      "url": "https://finnhub.io/api/news?id=0ec17d483c797743dfcd884a96802b5c5e5151e6563c0334f445d3f314d0ed09"
    },
    {
      "headline": "Why Novo Nordisk Stock Sank by Nearly 4% Today",
      "source": "Yahoo",
      "datetime": 1750112488,
      "summary": "On top of that, an analyst cut his price target on the Denmark-based pharmaceutical company.  Novo Nordisk (NYSE: NVO) stock had a Monday to forget, as news from a top rival dampened sentiment on the Danish pharmaceutical company.  A price target cut from an analyst tracking the company only exacerb",
      "url": "https://finnhub.io/api/news?id=224b3bbd0e3886b0372e59e91800b16b5831cbd92f85a83adda589d0bc318ba8"
    },
    {
      "headline": "Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts",
      "source": "Yahoo",
      "datetime": 1750110302,
      "summary": "In the closing of the recent trading day, Eli Lilly (LLY) stood at $807.58, denoting a -1.44% move from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=929d97a6ffd380a3efa04f61eeb0ec686d96fb45dc377a7f87043d279505d742"
    },
    {
      "headline": "Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q1 2025 Update",
      "source": "SeekingAlpha",
      "datetime": 1750108183,
      "summary": "AQR Capital's Q1'25 portfolio hits $97.07B, with top picks in AAPL, NVDA, & AMZN. Active portfolio adjustments show a quantitative, diversified approach. See more.",
      "url": "https://finnhub.io/api/news?id=51b45bd42e92498ec52abd010edf461044394127b04a8428f9c402a3b43b4ef8"
    },
    {
      "headline": "Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push",
      "source": "Finnhub",
      "datetime": 1750104613,
      "summary": "June 17 - Eli Lilly will acquire gene-editing startup VerveTherapeutics for up to $1.3 billion, the companies saidon Tuesday, to boost its pipeline of experimental medicinesbeyond...",
      "url": "https://finnhub.io/api/news?id=88b6ce3f321c5422ada070912f6a86eb3b42806178899ce17c644ecc82f3fd26"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-05-27",
      "description": "xslF345X05/wk-form4_1748376794.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000156/xslF345X05/wk-form4_1748376794.xml"
    },
    {
      "form": "4",
      "date": "2025-05-20",
      "description": "xslF345X05/wk-form4_1747772733.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000154/xslF345X05/wk-form4_1747772733.xml"
    },
    {
      "form": "4",
      "date": "2025-05-20",
      "description": "xslF345X05/wk-form4_1747772668.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000152/xslF345X05/wk-form4_1747772668.xml"
    },
    {
      "form": "4",
      "date": "2025-05-20",
      "description": "xslF345X05/wk-form4_1747772589.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000150/xslF345X05/wk-form4_1747772589.xml"
    },
    {
      "form": "4",
      "date": "2025-05-20",
      "description": "xslF345X05/wk-form4_1747772518.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000148/xslF345X05/wk-form4_1747772518.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}